The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19
- PMID: 35839729
- PMCID: PMC9258419
- DOI: 10.1016/j.imbio.2022.152240
The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19
Abstract
Previous case reports have described patients with COVID-19-associated autoimmune hemolytic anemia (AIHA), and cold agglutinin disease (CAD) which is characterized by a positive direct antiglobulin (DAT) or "Coombs" test, yet the mechanism is not well understood. To investigate the significance of Coombs test reactivity among COVID-19 patients, we conducted a retrospective study on hospitalized COVID-19 patients treated at NMC Royal Hospital between 15 April and 30 May 2020. There were 27 (20%) patients in the Coombs-positive group and 108 (80%) in the Coombs-negative group. The cold agglutinin titer was examined in 22 patients due to symptoms suggestive of cold agglutinin disease, and all tested negative. We demonstrated a significant association with reactive Coombs test results in univariate analysis through clinical findings such as ICU admission rate, the severity of COVID-19, and several laboratory findings such as CRP, D-dimer, and hemoglobin levels lactate dehydrogenase, and RDW-CV. However, only hemoglobin levels and disease severity had a statistically significant association in multivariate analysis. A possible explanation of COVID-19-associated positive Coombs is cytokine storm-induced hyperinflammation, complement system activation, alterations of RBCs, binding of SARS-CoV-2 proteins to hemoglobin or its metabolites, and autoantibody production. Coombs-positive patients were tested for hemolysis using indirect bilirubin, consumed haptoglobin, and/or peripheral smear that ruled out any evidence of hemolysis. Understanding this etiology sheds new light on RBC involvement as a pathophysiological target for SARS-CoV-2 by interfering with their function; consequently, therapies capable of restoring RBC function, such as erythrocytapheresis, could be repurposed for the treatment of worsening severe and critical COVID-19.
Keywords: Anemia; Antiglobulin (Coombs) test; Erythrocytapheresis; Hemoglobinopathy; Hemolysis; Red blood cell.
Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
[Clinical and Laboratory Characteristics of Primary Autoimmune Hemolytic Anemia Patients with Negative Results of DAT by Tube Test But Positive Results by Microcolumn Gel Assay].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Oct;30(5):1532-1535. doi: 10.19746/j.cnki.issn.1009-2137.2022.05.035. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022. PMID: 36208261 Chinese.
-
Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia.Am J Hematol. 2009 Feb;84(2):98-101. doi: 10.1002/ajh.21336. Am J Hematol. 2009. PMID: 19105232
-
Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients.Int J Lab Hematol. 2021 Oct;43(5):1154-1158. doi: 10.1111/ijlh.13469. Epub 2021 Jan 18. Int J Lab Hematol. 2021. PMID: 33459487
-
Diagnosis and classification of autoimmune hemolytic anemia.Autoimmun Rev. 2014 Apr-May;13(4-5):560-4. doi: 10.1016/j.autrev.2013.11.010. Epub 2014 Jan 11. Autoimmun Rev. 2014. PMID: 24418298 Review.
-
Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review.Blood Cells Mol Dis. 2014 Apr;52(4):152-60. doi: 10.1016/j.bcmd.2013.12.003. Epub 2014 Jan 9. Blood Cells Mol Dis. 2014. PMID: 24411920 Review.
Cited by
-
Direct antiglobulin (Coombs) test in HIV-positive Talaromycosis marneffei patients.Med Mycol. 2024 Aug 2;62(8):myae077. doi: 10.1093/mmy/myae077. Med Mycol. 2024. PMID: 39127611 Free PMC article.
-
Alterations of erythropoiesis in Covid-19 patients: prevalence of positive Coombs tests and iron metabolism.Ther Adv Hematol. 2023 Sep 28;14:20406207231199837. doi: 10.1177/20406207231199837. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37780945 Free PMC article.
-
Clinical and laboratory profile of patients with positive direct antiglobulin test attended at a university hospital in Goias, Brazil.Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S65-S71. doi: 10.1016/j.htct.2024.04.118. Epub 2024 May 8. Hematol Transfus Cell Ther. 2024. PMID: 39095314 Free PMC article.
References
-
- Algassim A.A., Elghazaly A.A., Alnahdi A.S., Mohammed-Rahim O.M., Alanazi A.G., Aldhuwayhi N.A., Alanazi M.M., Almutairi M.F., Aldeailej I.M., Kamli N.A., Aljurf M.D. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann. Hematol. 2021;100(1):37–43. doi: 10.1007/s00277-020-04256-3. - DOI - PMC - PubMed
-
- Angileri, F., Légaré, S., Marino Gammazza, A., Conway de Macario, E., Macario, A. J. L., & Cappello, F. (2020). Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? In British Journal of Haematology (Vol. 190, Issue 2, pp. e92–e93). Blackwell Publishing Ltd. 10.1111/bjh.16883. - PMC - PubMed
-
- Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y.u., Dorgham K., Philippot Q., Rosain J., Béziat V., Manry J., Shaw E., Haljasmägi L., Peterson P., Lorenzo L., Bizien L., Trouillet-Assant S., Dobbs K., de Jesus A.A., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (New York, N.Y.) 2020;370(6515) doi: 10.1126/science.abd4585. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous